113 related articles for article (PubMed ID: 37783391)
1. Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy.
Zhang Y; Zhang Y; Tao H; Zhu J; Lu Y; Cheng F; Xiong Y; Liu J; Cai G; Zhang Z; Liang H; Chen Y; Zhang W
Cancer Lett; 2023 Nov; 576():216405. PubMed ID: 37783391
[TBL] [Abstract][Full Text] [Related]
2. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
[TBL] [Abstract][Full Text] [Related]
4. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
6. METTL3-m
Wang L; Yang Q; Zhou Q; Fang F; Lei K; Liu Z; Zheng G; Zhu L; Huo J; Li X; Peng S; Kuang M; Lin S; Huang M; Xu L
Cancer Lett; 2023 Apr; 559():216122. PubMed ID: 36898427
[TBL] [Abstract][Full Text] [Related]
7. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
8. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
9. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
10. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
Tan W; Zhang K; Chen X; Yang L; Zhu S; Wei Y; Xie Z; Chen Y; Shang C
J Adv Res; 2023 Feb; 44():173-183. PubMed ID: 36725188
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
[TBL] [Abstract][Full Text] [Related]
12. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract][Full Text] [Related]
13. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
14. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.
Wang S; Zhou L; Ji N; Sun C; Sun L; Sun J; Du Y; Zhang N; Li Y; Liu W; Lu W
Drug Resist Updat; 2023 Jul; 69():100976. PubMed ID: 37210811
[TBL] [Abstract][Full Text] [Related]
15. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
16. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma.
Xu J; Ji L; Ruan Y; Wan Z; Lin Z; Xia S; Tao L; Zheng J; Cai L; Wang Y; Liang X; Cai X
Signal Transduct Target Ther; 2021 May; 6(1):190. PubMed ID: 34001851
[TBL] [Abstract][Full Text] [Related]
17. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
18. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.
Han WY; Wang J; Zhao J; Zheng YM; Chai XQ; Gao C; Cai JB; Ke AW; Fan J; Gao PT; Sun HX
Cancer Lett; 2023 Aug; 568():216259. PubMed ID: 37279851
[TBL] [Abstract][Full Text] [Related]
19. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang M; Long J; Yao Z; Zhao Y; Zhao Y; Liao J; Lei K; Xiao H; Dai Z; Peng S; Lin S; Xu L; Kuang M
Cancer Res; 2023 Jan; 83(1):89-102. PubMed ID: 36102722
[TBL] [Abstract][Full Text] [Related]
20. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
